JP2015536146A - 細胞特異的に有効な新規ヌクレオチド分子及び該分子使用のための投与キット - Google Patents
細胞特異的に有効な新規ヌクレオチド分子及び該分子使用のための投与キット Download PDFInfo
- Publication number
- JP2015536146A JP2015536146A JP2015542269A JP2015542269A JP2015536146A JP 2015536146 A JP2015536146 A JP 2015536146A JP 2015542269 A JP2015542269 A JP 2015542269A JP 2015542269 A JP2015542269 A JP 2015542269A JP 2015536146 A JP2015536146 A JP 2015536146A
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide molecule
- nucleotide
- molecule
- peptide
- ampoule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002773 nucleotide Substances 0.000 title claims abstract description 84
- 125000003729 nucleotide group Chemical group 0.000 title claims abstract description 82
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 44
- 229920000642 polymer Polymers 0.000 claims abstract description 22
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 8
- 108020004999 messenger RNA Proteins 0.000 claims description 40
- 239000003708 ampul Substances 0.000 claims description 16
- 239000004055 small Interfering RNA Substances 0.000 claims description 15
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 230000004071 biological effect Effects 0.000 claims description 11
- 108091005804 Peptidases Proteins 0.000 claims description 7
- 239000004365 Protease Substances 0.000 claims description 6
- 230000002779 inactivation Effects 0.000 claims description 5
- 230000004048 modification Effects 0.000 claims description 5
- 238000012986 modification Methods 0.000 claims description 5
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 4
- 230000015556 catabolic process Effects 0.000 claims description 4
- 238000006731 degradation reaction Methods 0.000 claims description 4
- 239000002679 microRNA Substances 0.000 claims description 4
- 238000001890 transfection Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 229920002873 Polyethylenimine Polymers 0.000 claims description 2
- 239000013024 dilution buffer Substances 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 239000011535 reaction buffer Substances 0.000 claims description 2
- 239000000523 sample Substances 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 abstract description 25
- 108020004707 nucleic acids Proteins 0.000 abstract description 24
- 102000039446 nucleic acids Human genes 0.000 abstract description 24
- 230000008827 biological function Effects 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 238000007385 chemical modification Methods 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 28
- 229920002477 rna polymer Polymers 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 18
- 108020004459 Small interfering RNA Proteins 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 108091023037 Aptamer Proteins 0.000 description 10
- 230000031018 biological processes and functions Effects 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 8
- 230000014616 translation Effects 0.000 description 8
- 239000013566 allergen Substances 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- 102000035195 Peptidases Human genes 0.000 description 6
- 108091027076 Spiegelmer Proteins 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000003308 immunostimulating effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 235000019419 proteases Nutrition 0.000 description 4
- 210000003705 ribosome Anatomy 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 108700011259 MicroRNAs Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108091005685 RIG-I-like receptors Proteins 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 description 2
- 102100020872 Leucyl-cystinyl aminopeptidase Human genes 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102000004018 Caspase 6 Human genes 0.000 description 1
- 108090000425 Caspase 6 Proteins 0.000 description 1
- 108090000567 Caspase 7 Proteins 0.000 description 1
- 102100035904 Caspase-1 Human genes 0.000 description 1
- 108090000426 Caspase-1 Proteins 0.000 description 1
- 102100032616 Caspase-2 Human genes 0.000 description 1
- 108090000552 Caspase-2 Proteins 0.000 description 1
- 102100029855 Caspase-3 Human genes 0.000 description 1
- 102100025597 Caspase-4 Human genes 0.000 description 1
- 101710090338 Caspase-4 Proteins 0.000 description 1
- 102100038916 Caspase-5 Human genes 0.000 description 1
- 101710090333 Caspase-5 Proteins 0.000 description 1
- 102100038902 Caspase-7 Human genes 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 108090000538 Caspase-8 Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 235000000509 Chenopodium ambrosioides Nutrition 0.000 description 1
- 235000005490 Chenopodium botrys Nutrition 0.000 description 1
- 244000098897 Chenopodium botrys Species 0.000 description 1
- 108010022172 Chitinases Proteins 0.000 description 1
- 102000012286 Chitinases Human genes 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 108091000069 Cystinyl Aminopeptidase Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000002494 Endoribonucleases Human genes 0.000 description 1
- 108010093099 Endoribonucleases Proteins 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010010369 HIV Protease Proteins 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000952099 Homo sapiens Antiviral innate immune response receptor RIG-I Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 102100034872 Kallikrein-4 Human genes 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 241000237536 Mytilus edulis Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101710114878 Phospholipase A-2-activating protein Proteins 0.000 description 1
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 1
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 108010024383 kallikrein 4 Proteins 0.000 description 1
- 235000020638 mussel Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- BLFWHYXWBKKRHI-JYBILGDPSA-N plap Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@@H](N)CCC(O)=O BLFWHYXWBKKRHI-JYBILGDPSA-N 0.000 description 1
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
−生物学的に有効な分子を含み、且つ他のものも含むことができる少なくとも1本のアンプル(アンプルA)
−トランスフェクションシステム、例えば細胞透過性ペプチド、ナノ粒子、ポリエチレンイミン又は脂質を含む少なくとも1本の他のアンプル(アンプルB)
−生物学的に有効な分子に結合するための他の構成要素又はトランスフェクションシステムを含む少なくとも1本の他のアンプル(アンプルC)
−アンプルA、B及びCの内容物に対する希釈バッファー及び反応バッファー
−アンプル内容物からなる混合物を、標的細胞を含む媒体に注入するためのカニューレを備える1本以上のプローブ若しくは注射器及びその他の必要な器材
−使用又は投与のための使用説明書
RNAは、その配列が毒性タンパク質又はペプチドの1以上のセグメントに対して、或いは全毒性タンパク質又はペプチドをコーヂするよう選択することができる。例としては、細菌性毒素、例えばジフテリア、アントラックスA、アントラックスB、ボツリヌストキシン又は高等生物(イモガイ、ヘビ、トカゲ、昆虫、クモ、サソリ)の毒素が挙げられる。
特に細胞表面におけるアレルゲンの発現を引き起こす輸送配列と組み合わせると、アレルゲンが免疫系に進入できるようになる。アレルゲンをHLA配列(特に配列に前後して)、或いはHLA配列内部の一部位に組み合わせることにより、アレルゲンとHLAが共に細胞表面に発現されることが特に好ましい。アレルゲンとしては、非ヒトアレルゲン(例えばアンブロシア)が特に好適である。
1a、1b 阻害されたmRNA
2 リボソーム
3a、3b ペプチド
Claims (13)
- 細胞に導入するための22塩基長以上の一本鎖又は二本鎖ヌクレオチド分子であって、前記ヌクレオチド分子が該分子不活性化のために少なくとも1個のペプチド又はポリマーに結合されており、前記ペプチド又はポリマーは前記分子の生物学的効果を阻害し、且つ酵素によって分解され得ることにより生物学的効果が再び誘起されることを特徴とするヌクレオチド分子。
- 前記ヌクレオチド分子を阻害するために、プロテアーゼの分解配列を含む少なくとも1個のペプチドが結合されることを特徴とする、請求項1に記載のヌクレオチド分子。
- 前記ヌクレオチド分子を阻害するために、少なくとも1個のペプチドが、ヌクレオチドの両末端が互いに結合されるように該ヌクレオチドの主鎖部分に結合されることを特徴とする、請求項2に記載のヌクレオチド分子。
- 前記ヌクレオチド分子を阻害するために、少なくとも1個のペプチドがヌクレオチドの末端の間で結合されることを特徴とする、請求項2に記載のヌクレオチド分子。
- 前記ヌクレオチド分子を阻害するために、酵素によって分解され得る少なくとも1個のポリマーが結合されることを特徴とする、請求項1に記載のヌクレオチド分子。
- 前記ヌクレオチド分子を阻害するために、酵素によって分解され得る、少なくとも1個のポリマーと少なくとも1個のペプチドとの組合せが結合されることを特徴とする、請求項1に記載のヌクレオチド分子。
- 前記ヌクレオチド分子はmRNAであることを特徴とする、請求項1〜5のいずれか一項以上に記載のヌクレオチド分子。
- 前記ヌクレオチド分子はmiRNAであることを特徴とする、請求項1〜5のいずれか一項以上に記載のヌクレオチド分子。
- 前記ヌクレオチド分子はDNAであることを特徴とする、請求項1〜5のいずれか一項以上に記載のヌクレオチド分子。
- 前記ヌクレオチド分子はshRNAであることを特徴とする、請求項1〜5のいずれか一項以上に記載のヌクレオチド分子。
- 前記ヌクレオチド分子はPNAであることを特徴とする、請求項1〜5のいずれか一項以上に記載のヌクレオチド分子。
- 前記ヌクレオチド分子は他の修飾、特にLNAを含むことを特徴とする、請求項1〜10のいずれか一項以上に記載のヌクレオチド分子。
- ヌクレオチド分子を含み、且つ他のものも含み得る少なくとも1本のアンプル(アンプルA)と、
トランスフェクションシステム、例えば細胞透過性ペプチド、ナノ粒子、ポリエチレンイミン又は脂質を含む少なくとも1本の他のアンプル(アンプルB)と、
生物学的に有効な分子に結合するための他の構成要素又はトランスフェクションシステムを含む少なくとも1本の他のアンプル(アンプルC)と、
アンプルAとアンプルBの内容物に対する希釈バッファー及び反応バッファーと、
アンプル内容物からなる混合物を、標的細胞を含む媒体に注入するためのカニューレを備える1本以上のプローブ若しくは注射器及びその他の必要な器材と、
使用又は投与のための使用説明書と、
を少なくとも含む請求項1〜10に記載のヌクレオチド分子を使用及び投与するための投与キット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102012022596.2A DE102012022596B4 (de) | 2012-11-15 | 2012-11-15 | Neue zellspezifisch wirksame Nukleotid-Moleküle und Applikationskit zu deren Anwendung |
DE102012022596.2 | 2012-11-15 | ||
PCT/EP2013/073887 WO2014076213A1 (de) | 2012-11-15 | 2013-11-14 | Neue zellspezifisch wirksame nukleotid-moleküle und applikationskit zu deren anwendung |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2015536146A true JP2015536146A (ja) | 2015-12-21 |
Family
ID=49885191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015542269A Pending JP2015536146A (ja) | 2012-11-15 | 2013-11-14 | 細胞特異的に有効な新規ヌクレオチド分子及び該分子使用のための投与キット |
Country Status (7)
Country | Link |
---|---|
US (1) | US20160193362A1 (ja) |
EP (1) | EP2920305A1 (ja) |
JP (1) | JP2015536146A (ja) |
CN (1) | CN105051191A (ja) |
DE (1) | DE102012022596B4 (ja) |
HK (1) | HK1211055A1 (ja) |
WO (1) | WO2014076213A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016023974A1 (de) * | 2014-08-14 | 2016-02-18 | Friedrich-Schiller-Universität Jena | Peptid zur verwendung in der reduktion von nebenwirkungen in form von immunstimulatorischen reaktionen/effekten |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100009446A1 (en) * | 2007-02-15 | 2010-01-14 | Friedrich-Schiller-Universitaet Jena | Biologically active molecules, particularly based on pna and sirna, method for the cell-specific activation thereof, and application kit to be administered |
WO2011085720A1 (de) * | 2010-01-14 | 2011-07-21 | Universitätsklinikum Jena | Biologisch wirksame moleküle zur beeinflussung von virus-, bakterien-, parasiten-infizierten zellen und/oder tumorzellen und verfahren zu deren anwendung |
JP2012520060A (ja) * | 2009-03-13 | 2012-09-06 | フリードリヒ−シラー−ユニバーシタット イエナ | siRNAに基づく細胞特異的な有効分子、該分子製造のための適用キット及び該分子の使用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
EP0998577B1 (en) * | 1997-07-24 | 2004-10-27 | Perseptive Biosystems, Inc. | Conjugates of transporter peptides and nucleic acid analogs, and their use |
US8137695B2 (en) * | 2006-08-18 | 2012-03-20 | Arrowhead Madison Inc. | Polyconjugates for in vivo delivery of polynucleotides |
SI1407044T2 (en) | 2000-12-01 | 2018-03-30 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Small RNA molecules that mediate RNA interference |
WO2005021712A2 (en) * | 2003-06-25 | 2005-03-10 | Georgia Tech Research Corporation | Modified molecular beacons |
DE102010022937A1 (de) * | 2010-06-04 | 2011-12-08 | Universitätsklinikum Jena | Zellspezifisch aktivierbare biologisch wirksame Moleküle auf Grundlage von siRNA, Verfahren zu deren Aktivierung sowie Applikationskit zur Verabreichung |
CA3131967A1 (en) * | 2010-12-29 | 2012-07-05 | F. Hoffman-La Roche Ag | Small molecule conjugates for intracellular delivery of nucleic acids |
-
2012
- 2012-11-15 DE DE102012022596.2A patent/DE102012022596B4/de active Active
-
2013
- 2013-11-14 WO PCT/EP2013/073887 patent/WO2014076213A1/de active Application Filing
- 2013-11-14 JP JP2015542269A patent/JP2015536146A/ja active Pending
- 2013-11-14 EP EP13814439.9A patent/EP2920305A1/de not_active Withdrawn
- 2013-11-14 US US14/442,655 patent/US20160193362A1/en not_active Abandoned
- 2013-11-14 CN CN201380066844.XA patent/CN105051191A/zh active Pending
-
2015
- 2015-12-01 HK HK15111778.8A patent/HK1211055A1/xx unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100009446A1 (en) * | 2007-02-15 | 2010-01-14 | Friedrich-Schiller-Universitaet Jena | Biologically active molecules, particularly based on pna and sirna, method for the cell-specific activation thereof, and application kit to be administered |
JP2012520060A (ja) * | 2009-03-13 | 2012-09-06 | フリードリヒ−シラー−ユニバーシタット イエナ | siRNAに基づく細胞特異的な有効分子、該分子製造のための適用キット及び該分子の使用 |
WO2011085720A1 (de) * | 2010-01-14 | 2011-07-21 | Universitätsklinikum Jena | Biologisch wirksame moleküle zur beeinflussung von virus-, bakterien-, parasiten-infizierten zellen und/oder tumorzellen und verfahren zu deren anwendung |
Also Published As
Publication number | Publication date |
---|---|
CN105051191A (zh) | 2015-11-11 |
DE102012022596B4 (de) | 2017-05-04 |
WO2014076213A1 (de) | 2014-05-22 |
US20160193362A1 (en) | 2016-07-07 |
EP2920305A1 (de) | 2015-09-23 |
HK1211055A1 (en) | 2016-05-13 |
DE102012022596A1 (de) | 2014-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7412586B2 (ja) | VI-E型及びVI-F型CRISPR-Casシステム並びにそれらの使用 | |
Lundin et al. | Biological activity and biotechnological aspects of locked nucleic acids | |
JP6165723B2 (ja) | B型肝炎ウイルスの遺伝子発現を阻害するための組成物および方法 | |
Di Giusto et al. | Construction, stability, and activity of multivalent circular anticoagulant aptamers | |
JP5296328B2 (ja) | 1本鎖環状rnaおよびその製造方法 | |
Hirao et al. | DNA aptamer generation by ExSELEX using genetic alphabet expansion with a mini-hairpin DNA stabilization method | |
Khosravi et al. | Site-directed RNA editing: recent advances and open challenges | |
JP5873808B2 (ja) | ウイルス、バクテリア、寄生生物に感染した細胞及び/又は腫瘍細胞に影響を及ぼす生物学的有効分子群、及び該分子群を適用するための方法 | |
Taylor et al. | Towards applications of synthetic genetic polymers in diagnosis and therapy | |
JP2024518546A (ja) | 修飾されたmRNA、修飾された非コードRNA、およびその使用 | |
JP2015536146A (ja) | 細胞特異的に有効な新規ヌクレオチド分子及び該分子使用のための投与キット | |
ES2665274T5 (es) | Nuevas formas adicionales de moléculas de ARN de interferencia | |
TWI606058B (zh) | Nucleic acid complex and nucleic acid polysaccharide complex | |
KR20240017367A (ko) | 클래스 ii, v형 crispr 시스템 | |
AU2022245243A1 (en) | Novel crispr enzymes, methods, systems and uses thereof | |
WO2020033938A1 (en) | Programmable conditional sirnas and uses thereof | |
Reza et al. | Therapeutic genome mutagenesis using synthetic donor DNA and triplex-forming molecules | |
US11306310B2 (en) | MicroRNA inhibitor | |
AU784832B2 (en) | Self-cleaving RNA sequences and their use for the control of protein synthesis | |
US11999954B2 (en) | Programmable conditional SIRNAS and uses thereof | |
Baker et al. | Oligonucleotide analogues with locked-amide linkages have therapeutic potential | |
Kundu | Directed Evolution of a Novel Heterochiral Ribonuclease Ribozyme and Kinetic Characterization of Heterochiral DNA Strand Displacement Reactions | |
JP2023532007A (ja) | Rna断片を調節するための人工rna | |
TW202200607A (zh) | 用於核糖核酸藥物療法傳遞的核糖核蛋白 | |
CN110312798A (zh) | 用于基因组修饰的稳定剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161108 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161213 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20161213 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170929 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171031 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180529 |